Prognostic factors in follicular lymphoma in the rituximab era: How to identify a high-risk patient?

Biomedical Papers

Volumn 155, Issue 2, 2011, Pages 99-108

  Prochazka, Vit ^a   Papajik, Tomas ^a   Jarosova, Marie ^a   Indrak, Karel ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

FLIPI; Follicular lymphoma; Microenvironment; Molecular remission; PET; Prognostic factors; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; DISEASE FREE SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOLOGY; MORTALITY; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 79960221033     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2011.015     Document Type: Article

References (90)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. 2001. Blood 2006;107:265-76.
2. Trneny M, Vasova I, Pytlik R, Belada D, Jankovska M, Kubackova K, Salkova J, Koleskova E, Hofmanova Z, Hrabetova S, Kajaba V, Sykorova A, Pirnos J, Pribylova J, Svecova J, Ciberova J, Bolomska I, Skacelikova E, Brejcha M, Adamova D, Frankova H, Barsova L, Benesova K, Senigl V, Campr V, Boudova L, Stritesky J, Petrova M, Krejcova H, Prochazka B, Klener P. The Non-Hodgkin's lymphoma subtypes distribution and survival in Czech Republic. Klinicka onkologie 2007;20:341-348.
3. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
4. Ghielmini M, Schmitz SF, Bürki K, Pichert G, Betticher DC, Stupp R, Wernli M, Lohri A, Schmitter D, Bertoni F, Cerny T. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11(Suppl 1):123-6.
5. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86.
6. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
7. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8.
8. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patiens with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14.
9. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-14.
10. Vidal L, Gafter-Gvili A, Leibovici L, Dreyling M, Ghielmini M, Hsu Schmitz SF, Cohen A, Shpilberg O. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-55.
11. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8.
12. Azad A, Campbell P. High rates of infection associated with the use of maintenance rituximab monotherapy in non-Hodgkin lymphoma. Intern Med J 2009;39:778-9.
13. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G,Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64.
14. Rohatiner A, Radford J, Deakin D, Earl H, Love SB, Price O, Wilson A, Lister TA. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma. Br J Cancer 2001;85:29-35.
15. Rohatiner AZ, Gregory WM, Peterson B, Borden E, Solal-Celigny P, Hagenbeek A, Fisher RI, Unterhalt M, Arranz R, Chisesi T, Aviles A, Lister TA. Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-23.
16. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Scalabrini DR, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surfoval advantage. Blood 2008;111:4004-13.
17. Valkova V, Trneny M. [The current role of haematopoietic stem cell transplantation in the treatment of lymphomas--review]. Klin Onkol 2010;23:155-64.
18. Witzens-Harig M, Dreger P. Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 2010;51:967-74.
19. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010;92:246-54.
20. Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, Tilly H, Michaux L, Chèze S, Coiffier B, Solal-Céligny P. Lowgrade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients-a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-505.
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
22. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz- Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
23. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, Magagnoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-9.
24. van de Schans SA, Steyerberg EW, Nijziel MR, Creemers GJ, Janssen-Heijnen ML, van Spronsen DJ. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009;20:1697-702.
25. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated frontline with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504-8.
26. Montoto S, Lopez-Guillermo A, Altes A, Perea G, Ferrer A, Camós M, Villela L, Bosch F, Esteve J, Cervantes F, Bladé J, Nomdedeu B, Campo E, Sierra J, Montserrat E. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol 2004;15:1484-9.
27. Keeney GE, Gooley TA, Pham RN, Press OW, Pagel JM, Petersdorf SH, Maloney DG, Bensinger W, Holmberg L, Gopal AK. The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patiens undergoing autologous hematopoietic stem cell transplantation. Leuk Lymphoma 2007;48:1961-7.
28. Vose JM, Bierman PJ, Loberiza FR, Lynch JC, Bociek GR, Weisenburger DD, Armitage JO. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008;14:36-42.
29. Gine E, Montoto S, Bosch F, Arenillas L, Mercadal S, Villamor N, Martínez A, Colomo L, Campo E, Montserrat E, López- Guillermo A. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 2006;17:1539-45.
30. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Céligny P. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62.
31. Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, Rattotti S, Pascutto C, Paulli M, Lazzarino M. Validation of follicular lymphoma international prognostic index 2 (FLIPI 2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010;149:455-7.
32. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS, Malpas JS, Lister TA. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.
33. Horning SJ. Natural history of and therapy for the indolent non- Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
34. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response kriteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
35. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M, Barbui T, Bernasconi C, Dastoli G, Fuga G, Gamba E, Gargantini L, Gattei V, Lauria F, Lazzarino M, Mandelli F, Morra E, Pulsoni A, Ribersani M, Rossi-Ferrini PL, Rupolo M, Tura S, Zagonel V, Zaja F, Zinzani P, Reato G, Foa R. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856-62.
36. Hirt C, Schuler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, Neser S, Assmann M, Srock S, Rohrberg R, Dachselt K, Leithäuser M, Rabkin CS, Herold M, Dölken G. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients. Br J Haematol 2008;141:631-40.
37. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A. Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 2009;27:6094-100.
38. Papajik T, Jedlickova K, Kriegova E, Jarosova M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma 2001;48:501-5.
39. van Oers MH, Tonnissen E, Van Glabbeke M, Giurgea L, Jansen JH, Klasa R, Marcus RE, Wolf M, Kimby E, Vranovsky A, Holte H, Hagenbeek A, van der Reijden BA. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study. J Clin Oncol 2010;28:2246-52.
40. Prochazka V, Papajik T. Molecular remission in follicular lymphoma: Is the era of residual disease monitoring over?. J Clin Oncol 2010;28, in press.
41. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999;20:13-20.
42. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2006:259-65,510-1.
43. Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/ CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol 2009;88:425-32.
44. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86.
45. Bodet-Milin C, Kraeber-Bodéré F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 2008;93:471-2.
46. Mena LM, Setoain X, Abrisqueta P, Rodriguez S, Lopez-Guillermo A, Fuster D, Lafuente S, Fuertes S, Rubí S, Pons F. Histological transformation of follicular lymphoma after treatment: a case evaluated with PET/CT. Clin Nucl Med 2009;34:793-4.
47. Wohrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, Raderer M, Hoffmann M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol 2006;17:780-4.
48. Papajik T, Myslivecek M, Sedova Z, Buriankova E, Prochazka V, Koranda P, Raida L, Kubová Z, Palová M, Kucerová L, Flodr P, Jarkovský J, Dušek L, Indrák K. Standardised uptake value of (18) F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Haematol 2011;86:32-7. doi: 10.1111/j.1600-0609.2010.01532.x.
49. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics 2010;30:269-91.
50. Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F] fluorodeoxyglucose positron emission tomography in the man agement of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma 2008;8:287-93.
51. Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, Cuggia M, Le Jeune F, Bahri H, Barge ML, Lamy T, Garin E. Diagnostic and prognostic impact of (18)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010;37:2307-14.
52. Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S. FDGPET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Ann Oncol 2010;21:1877-83.
53. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005;23:6358-63.
54. Ott G, Rosenwald A. Molecular pathogenesis of follicular lymphoma. Haematologica 2008;93:1773-6.
55. Limpens J, de Jong D, van Krieken JH, Price CG, Young BD, van Ommen GJ, Kluin PM. Bcl-2/JH rearrangements in benign lymphoidtissues with follicular hyperplasia. Oncogene 1991;6:2271-2276.
56. Baró C, Espinet B, Salido M, García M, Sánchez B, Florensa L, Bellosillo B, Serrano S, Solé F. Cryptic IGH/BCL2 rearrangements with variant FISH patterns in follicular lymphoma. Leuk Res 2010 [Epub ahead of print] doi:10.1016/j.leukres.2010.09.011
57. Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, Delabie J, Jaffe ES, Lister A, Fitzgibbon J, Staudt LM, Hartmann EM, Mueller-Hermelink HK, Campo E, Ott G, Rosenwald A. Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood 2009;114:826-34.
58. Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A, Monconduit M, Bastard C. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 1994;84:1043-9.
59. Höglund M, Sehn L, Connors JM, Gascoyne RD, Siebert R, Säll T, Mitelman F, Horsman DE. Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. Genes Chromosomes Cancer 2004;39:195-204.
60. Katzenberger T, Kalla J, Leich E, Stocklein H, Hartmann E, Barnickel S, Wessendorf S, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009;113:1053-61.
61. Dave SS. Follicular lymphoma and the microenvironment. Blood 2008;111:4427-8.
62. Solal-Céligny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010;92:246-54.
63. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-69.
64. Byers RJ, Sakhinia E, Joseph P, Glennie C, Hoyland JA, Menasce LP, Radford JA, Illidge T. Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. Blood 2008;111:4764-70.
65. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
66. Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F, Lamy T, Sonet A, Rousselet MC, Foussard C, Xerri L. High numbers of tumor-associated macrophages have an averse prognostic value that can be circumvented by rituximab in patiens with follicular lymphoma enrolled onto the GELAGOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6.
67. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-9.
68. Jacob MC, Piccinni MP, Bonnefoix T, Sotto MF, Couderc P, Bensa JC, Sotto JJ. T lymphocytes from invaded lymph nodes in patients with B-cellderived non-Hodgkin's lymphoma: reactivity toward the malignant clone. Blood 1990;75:1154-62.
69. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis 2003;8:45-53.
70. Fehervari Z, Sakaguchi S. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol 2004;16:1769-80.
71. Fehervari Z, Sakaguchi S. A paragon of self-tolerance: CD25+CD4+ regulatory T cells and the control of immune responses. Arthritis Res Ther 2004;6:19-25.
72. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, Gascoyne RD. The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 2010;115:289-95.
73. Procházka V., Papajík T., Kubová Z., Novák M., Pikalová Z., Rožmanová Š., Jarošová M., Indrák K. Transfuze Hematol. dnes 2009;15:224-8.
74. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 997;15:1110-7.
75. Gribben JG. How I treat indolent lymphoma. Blood 2007;109:4617-26.
76. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43-52.
77. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42.
78. Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006;91:176-83.
79. Fijen CA, Bredius RG, Kuijper EJ, Out TA, De Haas M, De Wit AP, Daha MR, De Winkel JG. The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol 2000;120:338-45.
80. Dijstelbloem HM, Scheepers RH, Oost WW, Stegeman CA, van der Pol WL, Sluiter WJ, Kallenberg CG, van de Winkel JG, Tervaert JW. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999;42:1823-7.
81. Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9.
82. Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007;7:286-90.
83. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti- CD20 monoclonal antipody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
84. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
85. Prochazka V, Rozmanova S, Papajik T, Jarosova M, Indrak K. Riskadapted immunochemotherapy overcomes the negative prognostic impact of the FCGRIIIA receptor genotype in patiens with follicular lymphoma. Haematologica 2007;92(Suppl 2):111.
86. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R, Rambaldi A. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patiens treated with sequential CHOP and rituximab. Haematologica 2007;92:1127-30.
87. Metha BA, Advani SH, Nadkarni SJ. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non- Hodgkin's lymphoma. Neoplasma 1988;35:61-8.
88. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004;294:15-22.
89. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 2005;19:835-40.
90. Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006;34:753-9.